The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.

about

The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.

Item

http://www.wikidata.org/entity/Q50102788

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

The cardiovascular effect of i ...... iew and network meta-analysis.

@en

The cardiovascular effect of i ...... iew and network meta-analysis.

@nl

type

Item

label

The cardiovascular effect of i ...... iew and network meta-analysis.

@en

The cardiovascular effect of i ...... iew and network meta-analysis.

@nl

prefLabel

The cardiovascular effect of i ...... iew and network meta-analysis.

@en

The cardiovascular effect of i ...... iew and network meta-analysis.

@nl

P1476

The cardiovascular effect of i ...... view and network meta-analysis

@en

P2093

Feng Sun

http://www.w3.org/2001/XMLSchema#string

Jun Yang

http://www.w3.org/2001/XMLSchema#string

Sanbao Chai

http://www.w3.org/2001/XMLSchema#string

Shanshan Wu

http://www.w3.org/2001/XMLSchema#string

Siyan Zhan

http://www.w3.org/2001/XMLSchema#string

Ting Cai

http://www.w3.org/2001/XMLSchema#string

Xiaochi Quan

http://www.w3.org/2001/XMLSchema#string

Yang Xu

http://www.w3.org/2001/XMLSchema#string

Yuan Zhang

http://www.w3.org/2001/XMLSchema#string

Zhirong Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants

Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials.

Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people

Evaluating the quality of evidence from a network meta-analysis.

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.

Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies.

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.

P304

243-249

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1080/14740338.2018.1424826

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrea Cipriani

P577

2018-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29320889

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes